Skip to main
TARA
TARA logo

TARA Stock Forecast & Price Target

TARA Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Protara Therapeutics Inc. is demonstrating substantial advancements in its therapeutic programs, particularly with TARA-002, which has shown a notable improvement in efficacy profiles over time, marked by 100% durability and an 80% salvage rate upon re-induction. Additionally, the company's intravenous choline chloride has exhibited significant liver health improvements in Phase 2 trials, outperforming placebo in managing intestinal failure associated liver disease (IFALD). With the potential for competitive efficacy, a strong safety profile, and flexible pricing strategies, Protara is well-positioned to enhance its market presence and achieve widespread adoption of its innovative treatments.

Bears say

Protara Therapeutics reported a significant net loss of $12.7 million in the fourth quarter of 2024, reflecting financial challenges despite its promising therapies. The company’s lead program, TARA-002, shows potential in treating non-muscle invasive bladder cancer (NMIBC), yet the competitive landscape could hinder its market acceptance, compounded by supply issues related to essential adjunct therapies. Additionally, concerns surrounding the effectiveness of intravenous choline chloride as a treatment for intestinal failure associated liver disease further contribute to the negative outlook, particularly in light of observed liver damage linked to dietary choline depletion.

TARA has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Protara Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Protara Therapeutics Inc (TARA) Forecast

Analysts have given TARA a Buy based on their latest research and market trends.

According to 8 analysts, TARA has a Buy consensus rating as of Jul 13, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Protara Therapeutics Inc (TARA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.